Adenovirus Vector Manufacturing Platform Using CIMmultus® QA Column To Produce Safer Vaccines Cheaper
By K. Vrabec, H. Jug, A. Mavri, I. Petrovic Koshmak, V. Fujs, M. Leskovec, and A. Štrancar
![Covid vaccine-GettyImages-1336518535 Covid vaccine-GettyImages-1336518535](https://vertassets.blob.core.windows.net/image/d6be3ebb/d6be3ebb-6202-4371-b004-c828b4d93d7a/375_250-covid_vaccine_gettyimages_1336518535.jpg)
After two decades, adenovirus has garnered renewed attention and is now employed as a delivery vehicle for COVID-19 vaccines. To reduce vaccine side effects, ensuring the purity of the virus is of utmost importance. Consequently, there is a continuous need for refining vaccine purity and enhancing impurity detection methods. In this study, we present a second-generation purification procedure for adenoviral vectors based on monolith chromatography, utilizing CIMmultus® QA and the accompanying analytical tools. This novel industrial process secures safer products and enhances purity at higher yields. Large-scale vaccine manufacturing during the pandemic represents significant challenges, primarily in terms of production time and costs. The high capacity of the CIMmultus® QA columns utilized in this process effectively overcomes the raw material supply bottlenecks.
Get unlimited access to:
Enter your credentials below to log in. Not yet a member of Life Science Leader? Subscribe today.